Screener
CytomX Therapeutics CTMX Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: CytomX Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211868
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Purchases of property and equipment | — | (119) |
| Purchases of short-term investments | (242,777) | (19,785) |
| Maturities of short-term investments | 50,000 | 50,500 |
| Net cash (used in) provided by investing activities | (192,777) | 30,596 |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock, net issuance cost | 228,351 | — |
| Proceeds from issuance of pre-funded warrants, net issuance cost | 5,855 | — |
| Proceeds from exercise of stock options | 281 | — |
Item 1. Condensed Financial Statements (Unaudited)
FAQ
- What is CytomX Therapeutics's investing cash flow?
- CytomX Therapeutics (CTMX) reported investing cash flow of -$192.78M in Q1 2026.
- How has CytomX Therapeutics's investing cash flow changed year-over-year?
- CytomX Therapeutics's investing cash flow decreased by 730.1% year-over-year, from $30.6M to -$192.78M.
- What is the long-term trend for CytomX Therapeutics's investing cash flow?
- Over 2 years (2022 to 2025), CytomX Therapeutics's investing cash flow has grown at a -21.7% compound annual growth rate (CAGR), from $98.26M to -$60.18M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about CytomX Therapeutics's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude